PCSK9 and coronary artery disorder: These observations have made PCSK9 a compelling drug target for the treatment and prevention of coronary heart disease, with three PCSK9-targeting drugs already approved for use in patients — alirocumab (a monoclonal antibody that binds PCSK9 protein in the blood), evolocumab (a monoclonal antibody that binds PCSK9 protein in the blood), and inclisiran (a small interfering RNA that knocks down PCSK9 mRNA levels in hepatocytes) — and a number of others in the drug development pipeline.